India, July 30 -- Alnylam Pharmaceuticals, Inc. (ALNY) reported second quarter net income of $164.5 million, compared to a net loss of $72.2 million a year ago. Profit per share totaled $1.21 versus a loss of $0.55 per share in the year-ago period. Non-GAAP Net income per common share increased to $1.84 from $0.28, prior year.
Total revenues increased to $1.29 billion in the second quarter from $773.7 million in the prior year period. Net product revenues rose to $1.17 billion from $672.2 million. The company said the increase was primarily due to growth from AMVUTTRA revenues driven by increased patient demand, mainly in patients with ATTR-CM in the U.S., and growth from an increased number of patients on GIVLAARI and OXLUMO, which was pa...